PhaseV has raised $65.0M in total across 2 funding rounds.
PhaseV's investors include Blumberg Capital, Cyberstarts VC, Aniq Kassam, Insight Partners, LionBird, RA Capital, Viola Ventures, Shlomo Kramer, FAST — by GETTYLAB, KRM Interests LLC, Y Combinator.
PhaseV is a Boston-based technology company that builds an AI and machine learning platform to optimize clinical development in the biopharma sector.[1][2][5] It serves over 30 global pharmaceutical companies and CROs across more than 20 therapeutic areas, including neurology, oncology, GI disorders, immunology, metabolic diseases, and rare diseases, by solving key challenges like high trial costs, long durations, low success rates, and inefficient patient recruitment through tools like Trial Optimizer, Causal ML, Causal Disease Modeling, and Clinical Operations.[2][3][4] The platform leverages causal machine learning, generative AI, and a data lake of real-world patient data to reduce trial costs by 50%, cut enrollment size and duration by 40%, boost success probability by over 30%, and accelerate time-to-market—for instance, shortening it by 15 months for one major pharma client.[4][2]
Founded in 2023, PhaseV has raised $65 million total, including a $50 million Series A in May 2025 co-led by Accel and Insight Partners, fueling rapid adoption and platform expansion.[2][3][4]
PhaseV was founded in 2023 by experts in molecular genetics, data science, and clinical development, with Raviv Pryluk, PhD, as CEO and co-founder.[1][2][3] Though headquartered in Boston, it originated as an Israeli startup, addressing pharma's pain points in clinical trial speed and cost-efficiency amid rising demands for precision medicine.[3][1] Early traction came quickly: by 2025, it secured partnerships with CROs like Alimentiv, Quanticate, NeuroSense Technologies, and iOMEDICO, while raising $15 million initially in 2023 before the oversized Series A.[3] Pivotal moments include case studies like redesigning a failed Type II diabetes trial for Oramed by identifying responsive patient subsets, and optimizing Phase 2/3 trials for biotech firms, reducing sample sizes by 10-15%.[5]
PhaseV rides the AI revolution in biopharma, where traditional trials face 90%+ failure rates and ballooning costs amid demands for faster, personalized medicine.[3][4] Timing is ideal post-2023 AI boom, with regulatory shifts favoring adaptive designs and real-world evidence, plus market forces like post-pandemic trial backlogs and precision therapy needs in oncology/immunology.[1][2] It influences the ecosystem by enabling virtual control arms, biomarker-guided therapies, and efficient R&D, partnering with CROs to scale AI adoption and reduce industry-wide inefficiencies—positioning it as a leader in "vertical AI" for clinical development.[2][4]
PhaseV is primed to dominate AI-driven clinical trials, expanding its platform with Series A funds to holistic end-to-end solutions amid surging biopharma AI investments.[2][4] Trends like multimodal data integration, regulatory AI approvals, and heterogeneous effect modeling will propel growth, potentially capturing more of the $50B+ clinical ops market. Its influence may evolve from optimizer to ecosystem enabler, powering precision medicine at scale and redefining trial success for global pharma. This Boston-born innovator, born from data science expertise, exemplifies how AI unlocks biopharma's next era of efficiency.[1][3]
PhaseV has raised $65.0M across 2 funding rounds. Most recently, it raised $50.0M Series A in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $50.0M Series A | Blumberg Capital, Cyberstarts VC, Aniq Kassam, Insight Partners, LionBird, RA Capital, Viola Ventures, Shlomo Kramer | |
| Oct 1, 2023 | $15.0M Seed | Blumberg Capital, Cyberstarts VC, FAST — by GETTYLAB, KRM Interests LLC, Viola Ventures, Y Combinator, Shlomo Kramer |
